CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.72B, above the global median of $1.18B
- FinancialsAltman Z-Score 3.51: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.23%Below 5Y avg (1.12%)
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Aug 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.52BCNY1.72B · vs all stocks (USD)
Trailing P/E
89.08xvs Biotechnology peers
Revenue (TTM)
1.56BCNY232.57M · vs all stocks (USD)
Profit Margin
8.27%vs Biotechnology peers
Beta
0.1660xvs all stocks
52-Week Change
101.13%vs all stocks
Forward Annual Dividend Yield
0.23%vs all stocks
Market Capitalization
11.52BCNY1.72B · vs all stocks (USD)
Enterprise Value
12.64BCNY1.89B · vs all stocks (USD)
Trailing P/E
89.08xvs Biotechnology peers
Forward P/E
79.19xvs Biotechnology peers
Price to Sales (TTM)
7.39xvs Biotechnology peers
Price to Book (MRQ)
4.87xvs Biotechnology peers
Enterprise to Revenue
8.11xvs Biotechnology peers
Enterprise to EBITDA
36.61xvs Biotechnology peers
Gross Margin
39.80%vs Biotechnology peers
Profit Margin
8.27%vs Biotechnology peers
Operating Margin
24.08%vs Biotechnology peers
Return on Assets (TTM)
2.09%vs Biotechnology peers
Return on Equity (TTM)
5.20%vs Biotechnology peers
Revenue (TTM)
1.56BCNY232.57M · vs all stocks (USD)
Revenue per Share (TTM)
3.30CNYUpdated Sep 20, 2026Quarterly Revenue Growth
88.80%vs Biotechnology peers
Gross Profit (TTM)
440.51MCNY65.73M · vs all stocks (USD)
EBITDA (TTM)
183.39MCNY27.37M · vs all stocks (USD)
Net Income (TTM)
128.83MCNY19.22M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
127.00%vs Biotechnology peers
Operating Cash Flow (TTM)
121.31MCNY18.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-103.44MCNY-15.44M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0500CNYUpdated Sep 20, 2026Forward Annual Dividend Yield
0.23%vs all stocks
Trailing Annual Dividend Rate
0.0500CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.23%vs all stocks
5-Year Average Dividend Yield
1.12%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
16.38MCNYFY2025 · Dec 31, 2025Revenue
1.18BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
986.85MCNYFY2025 · Dec 31, 2025Gross Profit
198.14MCNYFY2025 · Dec 31, 2025Operating Income
8.57MCNY1.28M · vs all stocks (USD)
Pre-tax Income
-65.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.24MCNYFY2025 · Dec 31, 2025Net Income
-62.97MCNYFY2025 · Dec 31, 2025EBIT
-18.97MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
183.39MCNYFY2025 · Dec 31, 2025Research & Development
59.50MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
62.78MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
46.24MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1000CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1000CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
550.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
550.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-62.97MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
7.94MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-2.10MCNYFY2025 · Dec 31, 2025Free Cash Flow
-226.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
464.07MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-62.97MCNYFY2025 · Dec 31, 2025Other Non-cash Items
46.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-16.76MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
31.22MCNYFY2025 · Dec 31, 2025Capital Expenditures
-224.14MCNYFY2025 · Dec 31, 2025Purchase of Investments
-170.00MCNYFY2025 · Dec 31, 2025Sale of Investments
174.26MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-219.88MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
950.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-903.78MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-54.77MCNYFY2025 · Dec 31, 2025Other Financing Charges
81.16MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
72.62MCNYFY2025 · Dec 31, 2025Shares Outstanding
538.65MSharesUpdated Sep 20, 2026Float Shares
413.04MSharesUpdated Sep 20, 2026% Held by Insiders
30.30%vs all stocks
% Held by Institutions
0.50%vs all stocks
Total Cash (MRQ)
492.40MCNY73.48M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9140CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.60BCNY238.62M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6711xvs Biotechnology peers
Current Ratio (MRQ)
1.28xvs Biotechnology peers
Book Value per Share (MRQ)
4.39CNYUpdated Sep 20, 2026Total Assets
4.40BCNY657.27M · vs all stocks (USD)
Total Current Assets
1.46BCNYFY2025 · Dec 31, 2025Total Liabilities
2.20BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.94BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
935.30MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.27BCNYFY2025 · Dec 31, 2025Cash
464.54MCNYFY2025 · Dec 31, 2025Cash Equivalents
18.44MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
482.98MCNYFY2025 · Dec 31, 2025Other Short-term Investments
954.50KCNYFY2025 · Dec 31, 2025Accounts Receivable
370.25MCNYFY2025 · Dec 31, 2025Inventory
379.93MCNYFY2025 · Dec 31, 2025Accounts Payable
348.04MCNYFY2025 · Dec 31, 2025Short-term Debt
841.52MCNYFY2025 · Dec 31, 2025Other Current Liabilities
39.21MCNYFY2025 · Dec 31, 2025Long-term Debt
809.46MCNYFY2025 · Dec 31, 2025Common Stock (Book)
538.65MCNYFY2025 · Dec 31, 2025Retained Earnings
209.49MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.20BCNY328.31M · vs all stocks (USD)
52-Week Low
9.40CNYUpdated Sep 20, 202652-Week High
24.18CNYUpdated Sep 20, 202652-Week Change
101.13%vs all stocks
Beta
0.1660xvs all stocks
50-Day MA
18.10CNYUpdated Sep 20, 2026200-Day MA
17.29CNYUpdated Sep 20, 2026Avg 10-Day Volume
41.26MSharesUpdated Sep 20, 2026Avg 30-Day Volume
32.44MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.2400CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.51: safe zoneNotable
Altman Z-Score: 3.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.72B, above the global median of $1.18BNotable
Market cap (USD): 1,718,464,406.118Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Edge Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Chipscreen Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hanall Biopharma Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule